The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus

Jie Wang, Hui-Qin Li, Xiao-Hua Xu, Xiao-Cen Kong, Rui Sun, Ting Jing, Lei Ye, Xiao-Fei Su, Jian-Hua Ma, Jie Wang, Hui-Qin Li, Xiao-Hua Xu, Xiao-Cen Kong, Rui Sun, Ting Jing, Lei Ye, Xiao-Fei Su, Jian-Hua Ma

Abstract

Aim. To compare the effects of once-weekly Dulaglutide with once-daily glargine in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus (T2DM). Method. A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9). All patients received either Dulaglutide or glargine treatments for 52 weeks. Continuous glucose monitoring systems (CGMS) were applied to them for two 72 h periods at before and after the treatment each. Patient general clinical data were collected and analyzed. Result. Fast blood glucose (FBG) of the glargine group declined more significantly than the Dulaglutide group after treatment (p < 0.05). The mean blood glucose (MBG), standard deviation of blood glucose (SDBG), mean amplitude of glycemic excursion (MAGE) within a day, the largest amplitude of glycemic excursion (LAGE), M-value, absolute means of daily difference (MODD) of glycemic excursion, the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05). The incidence of hypoglycemia was also similar between the two groups (p > 0.05). Though serum levels of TNF-α, IL-6, and 8-PGF2α all decreased, significant reduction was found in TNF-α and 8-PGF2α. TNF-α was only significantly reduced in the Dulaglutide group, while 8-PGF2α was seen in both groups. Conclusion. For T2DM patients with poorly controlled oral antidiabetic drugs, once-weekly Dulaglutide not only has the same effect on glucose fluctuation as once-daily glargine but also significantly reduced TNF-α and 8-PGF2α after a 52 week treatment protocol. This trial is registered with ClinicalTrials.gov NCT01648582.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Copyright © 2019 Jie Wang et al.

References

    1. Ogurtsova K., da Rocha Fernandes J. D., Huang Y., et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice. 2017;128:40–50. doi: 10.1016/j.diabres.2017.03.024.
    1. Leahy J. L. Pathogenesis of type 2 diabetes mellitus. Archives of Medical Research. 2005;36(3):197–209. doi: 10.1016/j.arcmed.2005.01.003.
    1. Sha X., Wang N., Deng X. Reasearch progress of GLP-1 and its analogues. Strait. Pharmaceutical Journal. 2011:1–6.
    1. Baggio L. L., Drucker D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157. doi: 10.1053/j.gastro.2007.03.054.
    1. Glaesner W., Vick A. M., Millican R., et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes/metabolism Research and Reviews. 2010;26(4):287–296. doi: 10.1002/dmrr.1080.
    1. Barrington P., Chien J. Y., Tibaldi F., Showalter H. D., Schneck K., Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes, Obesity and Metabolism. 2011;13(5):434–438. doi: 10.1111/j.1463-1326.2011.01365.x.
    1. Ban K., Noyan-Ashraf M. H., Hoefer J., Bolz S. S., Drucker D. J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–2350. doi: 10.1161/CIRCULATIONAHA.107.739938.
    1. Service F. J., O'Brien P. C. The relation of glycaemia to the risk of development and progression of retinopathy in the diabetic control and complications trial. Diabetologia. 2001;44(10):1215–1220. doi: 10.1007/s001250100635.
    1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. 1999. Geneva, Report Number: WHO/NCD/NCS/99.2.
    1. Kawamori R., Eliaschewitz F. G., Takayama H., Hayashida C. Y. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 2008;79(1):97–102. doi: 10.1016/j.diabres.2007.08.007.
    1. Blonde L., Jendle J., Gross J., et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. The Lancet. 2015;385(9982):2057–2066. doi: 10.1016/S0140-6736(15)60936-9.
    1. Jendle J., Testa M. A., Martin S., Jiang H., Milicevic Z. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Diabetes, Obesity and Metabolism. 2016;18(10):999–1005. doi: 10.1111/dom.12705.
    1. Probstfield J. L. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care. 2016;39(6):973–981. doi: 10.2337/dc15-2782.
    1. DeVries J. H. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405–1408. doi: 10.2337/db12-1610.
    1. Abdul–Ghani M., Migahid O., Megahed A., et al. Combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with poorly controlled type 2 diabetes on sulfonylurea plus metformin: the qatar study. Diabetes Care. 2017;40(3):325–331. doi: 10.2337/dc16-1738.
    1. Umpierrez G., Tofe Povedano S., Perez Manghi F., Shurzinske L., Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care. 2014;37(8):2168–2176. doi: 10.2337/dc13-2759.
    1. Nauck M., Weinstock R. S., Umpierrez G. E., Guerci B., Skrivanek Z., Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care. 2014;37(8):2149–2158. doi: 10.2337/dc13-2761.
    1. Giorgino F., Benroubi M., Sun J. H., Zimmermann A. G., Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) Diabetes Care. 2015;38(12):2241–2249. doi: 10.2337/dc14-1625.
    1. Araki E., Inagaki N., Tanizawa Y., Oura T., Takeuchi M., Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes, Obesity and Metabolism. 2015;17(10):994–1002. doi: 10.1111/dom.12540.
    1. Rosenstock J., Fonseca V. A., Gross J. L., et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37(8):2317–2325. doi: 10.2337/dc14-0001.
    1. Esposito K., Nappo F., Marfella R., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067–2072. doi: 10.1161/.
    1. Diamant M., Nauck M. A., Shaginian R., et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37(10):2763–2773. doi: 10.2337/dc14-0876.
    1. Wysham C., Blevins T., Arakaki R., et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care. 2014;37(8):2159–2167. doi: 10.2337/dc13-2760.
    1. Nauck M. A., Frossard J. L., Barkin J. S., et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647–654. doi: 10.2337/dc16-0984.
    1. Butler A. E., Galasso R., Matveyenko A., Rizza R. A., Dry S., Butler P. C. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia. 2010;53(1):21–26. doi: 10.1007/s00125-009-1556-8.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi